Lyell Immunopharma, Inc.
NASDAQ:LYEL
Overview | Financials
Company Name | Lyell Immunopharma, Inc. |
Symbol | LYEL |
Currency | USD |
Price | 1.27 |
Market Cap | 325,123,810 |
Dividend Yield | 0% |
52-week-range | 0.85 - 3.256 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Dr. Lynn Seely M.D., Ph.D. |
Website | https://www.lyell.com |
An error occurred while fetching data.
About Lyell Immunopharma, Inc.
Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD